Apellis Pharmaceuticals, Inc.
APLS
Κατάταξη σε μετοχές
#3324
Apellis Pharmaceuticals, Inc. is an actively operating biopharmaceutical... Apellis Pharmaceuticals, Inc. is an actively operating biopharmaceutical enterprise dedicated to the discovery, advancement, and commercialization of therapeutic agents. Its core strategy involves modulating the complement system to address various autoimmune and inflammatory conditions. The company's primary investigational compound, pegcetacoplan, is currently undergoing Phase III clinical evaluation. This advanced-stage therapy is being explored for its potential in treating geographic atrophy (GA), a form of age-related macular degeneration, and paroxysmal nocturnal hemoglobinuria (PNH). Beyond this lead candidate, Apellis also offers EMPAVELI (a systemic formulation of pegcetacoplan), which is being developed for a range of indications: in hematology for cold agglutinin disease (CAD) and thrombotic microangiopathy associated with hematopoietic stem cell transplantation (HSCT-TMA); in nephrology for C3 glomerulopathy (C3G) and immune complex membranoproliferative glomerulonephritis (IC-MPGN); and in neurology for amyotrophic lateral sclerosis (ALS). Furthermore, Apellis boasts a diverse pipeline including APL-2006, a dual-action C3 and VEGF inhibitor designed for complement-mediated disorders; APL-1030, a C3 inhibitor targeting multiple neurodegenerative diseases; and a novel combination therapy involving EMPAVELI with small interfering RNA (siRNA) to reduce hepatic C3 protein synthesis. Strategic alliances play a significant role, with a collaboration and licensing agreement in place with Swedish Orphan Biovitrum AB (publ) for the joint development of pegcetacoplan. The company also maintains a research partnership with Beam Therapeutics Inc., focusing on leveraging Beam's base editing technology to uncover new treatments for illnesses driven by complement system dysregulation. Established in 2009, Apellis Pharmaceuticals, Inc. operates from its headquarters in Waltham, Massachusetts.
Τιμή μετοχής
$41.03
Τελευταίος συγχρονισμός: 2026-05-15
Κεφαλαιοποίηση
$5.25B
Αλλαγή (1 ημέρα)
0.00%
Αλλαγή (1 έτος)
51.57%
Χώρα
US
Εμπόριο Apellis Pharmaceuticals, Inc. (APLS)
Κατηγορία
Healthcare
Κέρδη για την Apellis Pharmaceuticals, Inc. (APLS)
Κέρδη τον Mar 2026 TTM: $135.15M
Σύμφωνα με τις τελευταίες οικονομικές αναφορές της Apellis Pharmaceuticals, Inc., τα τρέχοντα κέρδη της εταιρείας είναι $135.15M. Το 2023, η εταιρεία παρουσίασε κέρδη $-526.50M, αύξηση σε σχέση με των κερδών του 2022 που ήταν $-651.50M. Τα κέρδη που εμφανίζονται σε αυτή τη σελίδα είναι πριν από τόκους και φόρους, γνωστά και ως EBIT.
Ιστορικό κερδών για την Apellis Pharmaceuticals, Inc. από 2013 έως 2026
Κέρδη στο τέλος κάθε έτους
| Έτος | Κέρδη | Αλλαγή |
|---|---|---|
| 2026 (TTM) | $135.15M | -168.70% |
| 2024 | $-196.72M | -62.64% |
| 2023 | $-526.50M | -19.19% |
| 2022 | $-651.50M | -12.67% |
| 2021 | $-746.00M | 117.47% |
| 2020 | $-343.03M | 12.58% |
| 2019 | $-304.71M | 138.98% |
| 2018 | $-127.50M | 149.97% |
| 2017 | $-51.01M | 88.04% |
| 2016 | $-27.13M | -41.69% |
| 2015 | $-46.52M | 314.14% |
| 2014 | $-11.23M | 183.49% |
| 2013 | $-3.96M | 0.00% |
Κέρδη παρόμοιων εταιρειών ή ανταγωνιστών
| Εταιρεία | Κέρδη | Διαφορά Κερδών | Χώρα |
|---|---|---|---|
| $5.27B | 3,803.11% |
US
|
|
| $-3.09B | -2,384.20% |
US
|
|
| $-4.02B | -3,071.75% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | 1,343.37% |
NL
|
